Elon Musk spent at least $225 million in Texas. The governor-elect who sued for Abbott emails and vowed a data center freeze won anyway
Hinojosa has questioned a $1.66 billion tax break for Musk’s $16.8 billion Terafab chip plant, and Democrats now control the Texas House.
What it means
- What to watch: Abbott Laboratories (ABT) is dealing with a legal or regulatory problem; these tend to move slowly, so the timeline matters as much as the charge.
- How the stock is trading: $ABT -2.02% in the latest session.
- Timing: It dropped mid-session, while New York was open, so the move beside it may already include the market's first reaction.
Where the stock stands
$ABT last traded at $113.18, -2.02% on the session. That puts it 14% shy of its 52-week high of $132.03 and 38% clear of its low of $81.97 — a little above the middle of the range. Over the year it has ranged 61% from low to high: a wide band — moves of several percent in a week come with the territory. These are latest-session quotes, not live prices — the live tape is on the $ABT page.
How much coverage it is getting
In the last 30 days Wook has filed 7 stories about $ABT — 2 of them this week. At its 30-day pace you would expect about 2 a week, so this week is somewhat busier than usual. Across those stories 0 read bullish, 7 neutral and 0 bearish — mostly headline writers keeping a straight face. This one reads neutral, so it sits squarely with the crowd. This is the only one from Fortune; the rest came from other outlets. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
Coming up
$ABT earnings in 84 days. These were on the calendar before this story and are not caused by it.
What to watch next
The $ABT page has the full chart, the filings and the valuation model behind every figure here. Want the facts without the spin? Read how two or three outlets frame the same story — where they agree is the news, where they differ is the angle. And Wook AI, up top, will happily do the math — how far $ABT sits from its high, or how this week's coverage stacks up.
How this analysis was made
Fortune published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ABT. It carried $225 million, $1.66 billion and $16.8 billion, shown as published and not recalculated. The preview above is the publisher's own wording.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Fortune published this on November 5, 2026. $ABT has moved -0.61% ($113.86 to $113.17). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.